

RHINOMED APPOINTS RHINOSWAB DISTRIBUTORS – SUPPLEMENTARY DISCLOSURE

14 September 2021: Melbourne, Australia. Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in wearable nasal and respiratory technology provides further details on the recently announced (10 September 2021) appointment of AntiMicrobial Technologies Group (AMT Group Australia Pty Ltd) as a distributor of Rhinoswab in Australia and BioTrading Benelux BV as a distributor in Belgium, the Netherlands and Luxembourg (Benelux).

Rhinomed announced that it has appointed AMT Group Australia Pty Ltd and BioTrading Benelux BV as distributors of the Rhinoswab and Rhinoswab Junior.

The distribution agreement with AMT Group Australia Pty Ltd is for an initial term of 12 months and provides AMTG the non-exclusive right to sell the Rhinoswab in Australia. AMT Group Australia Pty Ltd is a private company, based in Perth, WA. AMT Group Australia Pty Ltd delivers medical technologies to the Australian market with a focus on anti-microbial technologies (<https://www.amtg.com.au/>). The agreement is effective as of 19 August 2021.

The distribution agreement with BioTrading Benelux BV is for an initial three year term. BioTrading Benelux BV has been granted an exclusive right to sell the Rhinoswab in Belgium, the Netherlands and Luxembourg. BioTrading Benelux BV serves the biotechnology, pharmaceutical and clinical industries (<https://biotrading.com>). The agreement is effective as of 31 August 2021.

The agreements provide the distributor the right to sell the Rhinoswab in the territories, but does not inhibit Rhinomed's ability to sell or supply the Rhinoswab to Rapid antigen testing companies competing in those markets.

Other terms of the distribution agreements are standard for agreements of this nature.

This announcement discloses all material details as required under section 4.15 of Guidance Note 8.

For further information about Rhinoswab visit <https://www.rhinomed.global/about-rhino-med/sample-collection/>

This announcement has been authorised for release to the market by the Board.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a Melbourne, Australia based ASX listed medical device company that has developed a novel wearable nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.